'Unsustainable' to manufacture, ensure medicine supply beyond seven days — Pakistan pharma association

Pharmacists arrange medicines at a pharmacy shop in Peshawar on September 1, 2021. (AFP/File)
Short Url
Updated 07 February 2023
Follow

'Unsustainable' to manufacture, ensure medicine supply beyond seven days — Pakistan pharma association

  • Pakistani pharmaceutical manufacturers say rising cost of medicinal raw materials, depreciating rupee increasing cost of production
  • Government, drug regulatory authority failed to take measures to remedy ongoing situation, say Pakistani pharmaceutical manufacturers

ISLAMABAD: Pakistan's pharmaceutical industry on Monday warned it would be unable to manufacture and ensure the availability of medicines beyond seven days if the government does not take measures to being down the increasing cost of production for medicines.  

Pakistan, whose foreign exchange reserves have dwindled to a little over $3 billion, is desperately seeking external financing to avoid default. Its currency, the rupee, has declined to historic lows against the US dollar over the past couple of weeks, driving fears the country's import-dependent economy would see more inflation in the coming days.

Several factories have announced temporary closures across the country, largely owing to the increasing cost of raw materials. On Monday, the Pakistan Pharmaceutical Manufacturers Association (PPMA) former chairman, Qazi Mansoor Dilawar, wrote a letter to the health minister, the Drug Regulatory Authority of Pakistan (DRAP), and the health ministry to take remedial measures to bring down the cost of production.

He added that the depreciating rupee had increased the cost of imports, which had in turn, increased the cost of production of medicines.  

"In view of the foregoing and being compelled and constrained by the circumstances beyond the control of the pharmaceutical industry, it has become completely unsustainable to manufacture medicines and ensure their availability beyond the next 7 days," Dilawar wrote. 

He said the PPMA had repeatedly asked the government and DRAP to allow inflationary adjustments in the maximum retail prices of medicines, adding that failure to do so would result in the "inevitable collapse of the local pharmaceutical industry."

"The Federal Government and the DRAP have failed to take any measures whatsoever to protect the public en masse and remedy the ongoing situation," he wrote. 

Dilawar added that impediments in the pharma industry's growth would result in the denial of safe, potent and effective drugs to the masses.

Health Minister Abdul Qadir Patel and DRAP CEO Asim Rauf did not respond to requests by Arab News for comments. 


Pakistan regulator amends law to facilitate capital raising by listed companies

Updated 4 sec ago
Follow

Pakistan regulator amends law to facilitate capital raising by listed companies

  • The amendments address challenges faced by listed companies when raising further capital from existing shareholders through a rights issue
  • Previously, listed companies were prohibited from announcing a rights issue if the company, officials or shareholders had any overdue amounts

KARACHI: The Securities and Exchange Commission of Pakistan (SECP) has notified amendments to the Companies (Further Issue of Shares) Regulations 2020 to facilitate capital raising by listed companies while maintaining adequate disclosure requirements for investors, it announced on Monday,

The amendments address challenges faced by listed companies when raising further capital from existing shareholders through a rights issue. Previously, listed companies were prohibited from announcing a rights issue if the company, its sponsors, promoters, substantial shareholders, or directors had any overdue amounts or defaults appearing in their Credit Information Bureau (CIB) report.

This restriction constrained financially stressed yet viable companies from raising capital, even in circumstances where existing shareholders were willing to support revival, restructuring, or continuation of operations, according to the SECP.

“Under the amended framework, the requirement for a clean CIB report will not apply if the relevant persons provide a No Objection Certificate (NOC) regarding the proposed rights issue from the concerned financial institution(s),” the regulator said.

The notification of the amendments follows a consultative process in which the SECP sought feedback from market stakeholders, including listed companies, issue consultants, professional bodies, industry associations, law firms, and capital market institutions.

The amendments are expected to enhance market confidence, improve access to capital for listed companies, and strengthen transparency within the rights issue framework, according to the SECP.

“To ensure transparency and protect investors’ interests, companies in such cases must make comprehensive disclosures in the rights offer document,” the regulator said.

“These disclosures must include details of any defaults or overdue amounts, ongoing recovery proceedings, and the status of any debt restructuring.”

The revised regulations strike an “appropriate balance” between facilitating corporate rehabilitation and enabling investors to make informed investment decisions, the SECP added.